ContraFect
28 Wells Avenue, Third Floor
Yonkers, NY 10701
United States
Tel: 914-207-2300
Website: http://www.contrafect.com/
About ContraFect
ContraFect, a late-stage clinical biotechnology company focused on the discovery and development of biotherapeutics for life-threatening, drug-resistant infectious diseases is located in Westchester County, near New York City. We are dedicated to innovative drug development, leveraging novel technologies to create new therapies that address the high unmet medical needs of patients suffering from serious, antibiotic-resistant infections for which there are limited available treatment options. We are using ContraFect’s technical expertise to develop biotherapeutics for serious bacterial infections, including those caused by MDR and XDR strains that have high unmet medical needs, particularly products used in hospital-based markets.
It is an exciting time in our Company’s history as we advance our direct lytic agent (DLA) platform of lysins and amurin peptides into the clinic. Exebacase (CF-301), our lead lysin, is the first and only direct lytic agent to report promising results in Phase 2 and to advance to Phase 3 of development. Earlier last year, the FDA granted Breakthrough Therapy designation to exebacase for development as a treatment for MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics. The exebacase Phase 3 study, known as the DISRUPT Study (“ Direct Lysis of Staph aureus Resistant Pathogen Trial”) ongoing in the United States and will serve as the single pivotal trial to support the BLA. ContraFect also has an active discovery pipeline of DLAs discovered at ContraFect which are progressing towards the clinic with support from major funding agencies including the Department of Defense, CARB-X and the Cystic Fibrosis Foundation. Our lead IND candidate, CF-370, a lysin targets MDR Pseudomonas aeruginosa, a bacteria identified as a serious threat in the CDC’s Antibiotic Threats in the US, 2019 report.
93 articles with ContraFect
-
ContraFect CSO Steps Down
9/19/2016
-
ContraFect CEO to Retire, Will Relocate HQ from New York to Massachusetts
3/22/2016
-
ContraFect To Present At 27th Annual Piper Jaffray Healthcare Conference
12/1/2015
-
ContraFect Announces Third Quarter 2015 Financial And Operating Results
11/13/2015
-
ContraFect To Announce Third Quarter 2015 Results On November 12, 2015
11/9/2015
-
ContraFect To Present At 14th Annual BIO Investor Forum
10/14/2015
-
ContraFect Appoints Clinical Development Leader, Cara Cassino, M.D., As Chief Medical Officer
9/16/2015
-
ContraFect Announces Poster Presentation At The ICAAC/ICC 2015 Meeting For CF-301 For The Treatment Of Staph Aureus Infections, Including MRSA
9/9/2015
-
ContraFect Appoints Key Business Executives
9/8/2015
-
FDA Grants Fast Track Designation To ContraFect's CF-301, The First Of Its Lysins, Currently In Development For The Treatment Of Staph Aureus Infections, Including MRSA
8/17/2015
-
ContraFect Announces Second Quarter 2015 Financial And Operating Results
8/13/2015
-
ContraFect Provides Update On CF-301 Phase 1 Trial
8/11/2015
-
ContraFect To Announce Second Quarter 2015 Results On August 13, 2015
8/7/2015
-
ContraFect Announces Issuance Of Key Patent Covering Novel Lysin Technology
7/20/2015
-
ContraFect Announces $20,000,000 Private Placement
6/12/2015
-
ContraFect Announces First Healthy Volunteer Dosed With CF-301
5/21/2015
-
ContraFect Adds Former Cubist Executive Steven C. Gilman, PhD, To Board Of Directors As Executive Chairman
5/20/2015
-
ContraFect Announces First Quarter 2015 Results
5/15/2015
-
ContraFect Announces Commencement Of Phase 1 Clinical Trial Of Cf-301 For Staph Bloodstream Infections, Including MRSA
4/29/2015
-
ContraFect Announces Fourth Quarter And Full Year 2014 Results
4/6/2015